<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36752895</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1076</ISSN><JournalIssue CitedMedium="Internet"><Volume>182</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of pediatrics</Title><ISOAbbreviation>Eur J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.</ArticleTitle><Pagination><StartPage>1685</StartPage><EndPage>1695</EndPage><MedlinePgn>1685-1695</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00431-023-04837-0</ELocationID><Abstract><AbstractText Label="UNLABELLED">Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE). This study assessed the efficacy and side effects of HCQ in children with proliferative lupus nephritis (LN). This double-blind, randomized, placebo-controlled trial study was conducted on 60 children with proliferative LN classes III and IV treated with steroids and a mycophenolate (MMF) regimen. Patients were categorized into two groups, the HCQ group (n&#x2009;=&#x2009;30) and the placebo group (n&#x2009;=&#x2009;30). They were evaluated initially at 6- and a 12-month follow-up by mucocutaneous, ophthalmological examination, and investigations (BUN, creatinine, 24&#xa0;h proteinuria, triglycerides (TG), cholesterol, Antids-DNA, C3, C4). Disease activity was assessed using the SLE disease activity index (SLEDAI-2&#xa0;k). After 12&#xa0;months, TG, cholesterol, 24&#xa0;h proteinuria, Antids-DNA, and SLEDAI score were significantly decreased in the HCQ group (P: 0.002, 0.012, 0.031, 0.001, respectively). After 12&#xa0;months, the cumulative probabilities of developing primary end-points (LN partial and complete remission) were 40% and 60% in the HCQ group versus 53.3% and 36.7% in the placebo group (P: 0.002). After 12&#xa0;months, the HCQ group experienced mucocutaneous alopecia (3.3%), hyperpigmentation (10%), and ophthalmological mild retinal changes (6.7%), but they did not differ significantly from the placebo group.&#xa0; Cunclusion: HCQ improved the disease and LN activity in children with proliferative LN, with documented skin hyperpigmentation and mild retinal changes following HCQ use in a few cases. This study was registered on http://www.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">gov/ with trial registration number (TRN): NCT03687905, September 2018 "retrospectively registered."</AbstractText><AbstractText Label="WHAT IS KNOWN" NlmCategory="BACKGROUND">&#x2022; Hydroxychloroquine (HCQ) is documented as an adjunctive treatment in children with systemic lupus erythematosus (c-SLE) LN with efficacy in improving lupus musculoskeletal and mucocutaneous manifestations. &#x2022; Due to the paucity of studies, its effects and side effects in children with LN remain unclear.</AbstractText><AbstractText Label="WHAT IS NEW" NlmCategory="BACKGROUND">&#x2022; This pilot randomized clinical trial assessed the efficacy and adverse effects of HCQ in children with proliferative LN. &#x2022; HCQ had numerous advantages for LN, including rapid and sustained remission, antilipidemic effect, and rapid improvement of kidney functions.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gheet</LastName><ForeName>Fatma Sayed</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Tanta University, El-Geesh Street, Tanta, 31527, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Heba El-Sayed</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Tanta University, El-Geesh Street, Tanta, 31527, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Shahaby</LastName><ForeName>Waleed Ahmed</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Tanta University, El-Geesh Street, Tanta, 31527, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elrifaey</LastName><ForeName>Shymaa Mohamed</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Tanta University, El-Geesh Street, Tanta, 31527, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelnabi</LastName><ForeName>Hend Hassan</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0001-7940-9906</Identifier><AffiliationInfo><Affiliation>Pediatric Department, Faculty of Medicine, Tanta University, El-Geesh Street, Tanta, 31527, Egypt. hend.abdelnabi@med.tanta.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03687905</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Pediatr</MedlineTA><NlmUniqueID>7603873</NlmUniqueID><ISSNLinking>0340-6199</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Side effects</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36752895</ArticleId><ArticleId IdType="pmc">PMC10167107</ArticleId><ArticleId IdType="doi">10.1007/s00431-023-04837-0</ArticleId><ArticleId IdType="pii">10.1007/s00431-023-04837-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford) 2020;5(59):39&#x2013;51. doi: 10.1093/rheumatology/keaa381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, Spirou G, Bertsias A, Kabouraki E, Tzanakis I, Chatzi L, Sidiropoulos P, Boumpas DT, Bertsias GK (2017) Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis 76:1992&#x2013;2000.&#xa0;10.1136/annrheumdis-2017-211206. Epub 2017 Aug 5 PMID: 28780511.0015; PMCID: PMC7751166</Citation><ArticleIdList><ArticleId IdType="pubmed">28780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. Am Fam Physician. 2016;94:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">27548593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017;56:1945&#x2013;1961. doi: 10.1093/rheumatology/kex260.PMID:28968809.94(4):284-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex260.PMID:28968809.94(4):284-94</ArticleId><ArticleId IdType="pubmed">28968809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE) Expert Opin Drug Saf. 2017;16:411&#x2013;419. doi: 10.1080/14740338.2017.1269168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2017.1269168</ArticleId><ArticleId IdType="pubmed">27927040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, Lightstone L. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant. 2018;33:1604&#x2013;1610. doi: 10.1093/ndt/gfx318.PMID:29186572;PMCID:PMC7170714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfx318.PMID:29186572;PMCID:PMC7170714</ArticleId><ArticleId IdType="pmc">PMC7170714</ArticleId><ArticleId IdType="pubmed">29186572</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Rovin BH (2016) Current and emerging therapies for lupus nephritis. J Am Soc Nephrol 27:2929&#x2013;2939.&#xa0;10.1681/ASN.2016040415. Epub 2016 Jun 9 PMID: 27283496; PMCID: PMC5042683</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042683</ArticleId><ArticleId IdType="pubmed">27283496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema I, Wilhelmus S, Alpers C, Bruijn J, Colvin R, Cook T, D'Agati VD, Ferrario F, Haas M, Jennette JC, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93:789&#x2013;796. doi: 10.1016/j.kint.2017.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z, Urowitz MB, Gladman DD. SLEDAI-2 K for a 30-day window. Lupus. 2010;19:49&#x2013;50. doi: 10.1177/0961203309346505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309346505</ArticleId><ArticleId IdType="pubmed">19910390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K. Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV. Arthritis Res Ther. 2018;20:86. doi: 10.1186/s13075-018-1576-1.PMID:29720229;PMCID:PMC5932878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1576-1.PMID:29720229;PMCID:PMC5932878</ArticleId><ArticleId IdType="pmc">PMC5932878</ArticleId><ArticleId IdType="pubmed">29720229</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 2016;90:493&#x2013;501. doi: 10.1016/j.kint.2016.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.05.017</ArticleId><ArticleId IdType="pubmed">27378475</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G (2011) Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 6:2192&#x2013;2199. 10.2215/CJN.00910111. Epub 2011 Jul 28 PMID: 21799148; PMCID: PMC3359002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359002</ArticleId><ArticleId IdType="pubmed">21799148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggiero B, Vivarelli M, Gianviti A, Benetti E, Peruzzi L, Barbano G, Corona F, Ventura G, Pecoraro C, Murer L, Ghiggeri GM, Pennesi M, Edefonti A, Coppo R, Emma F. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant. 2013;28:1487&#x2013;1496. doi: 10.1093/ndt/gfs589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfs589</ArticleId><ArticleId IdType="pubmed">23345627</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol. 2015;35:455&#x2013;464. doi: 10.1016/j.semnephrol.2015.08.007.PMID:26573548;PMCID:PMC4653081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semnephrol.2015.08.007.PMID:26573548;PMCID:PMC4653081</ArticleId><ArticleId IdType="pmc">PMC4653081</ArticleId><ArticleId IdType="pubmed">26573548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W, Fortin PR. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62:863&#x2013;868. doi: 10.1002/art.27289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27289</ArticleId><ArticleId IdType="pubmed">20131232</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59:345&#x2013;364. doi: 10.1016/j.pcl.2012.03.007.PMID:22560574;PMCID:PMC3348509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcl.2012.03.007.PMID:22560574;PMCID:PMC3348509</ArticleId><ArticleId IdType="pmc">PMC3348509</ArticleId><ArticleId IdType="pubmed">22560574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152:550&#x2013;556. doi: 10.1016/j.jpeds.2007.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2007.09.019</ArticleId><ArticleId IdType="pubmed">18346514</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam LS, Li EK, Lam CW, Tomlinson B. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus. 2000;9:413&#x2013;416. doi: 10.1191/096120300678828541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300678828541</ArticleId><ArticleId IdType="pubmed">10981644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodis HN, Quismorio FP, Jr, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol. 1993;20:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">8496861</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba EF, Longterm BE. beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001;28:780&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">11327250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol. 1999;26:325&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">9972966</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis R, Seif AM, McGwin G Jr, Martinez-Martinez LA, Gonz&#xe1;lez EB, Dang N, Papalardo E, Liu J, Vil&#xe1; LM, Reveille JD, Alarc&#xf3;n GS, Pierangeli SS (2012) Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 8:830&#x2013;835.&#xa0;10.1177/0961203312437270. Epub 2012 Feb 17 PMID: 22343096; PMCID: PMC3808832</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808832</ArticleId><ArticleId IdType="pubmed">22343096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken) 2016;68:1295&#x2013;1302. doi: 10.1002/acr.22837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22837</ArticleId><ArticleId IdType="pubmed">26749299</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade Balbi V, Artur Silva C, Nascimento Pedrosa T, Maria Rodrigues Pereira R, de Arruda M, Campos L, Pires Leon E, Duarte N, Melechco Carvalho V, Gofinet Pasoto S, Cordeiro do Ros&#xe1;rio D, Kolachinski Brandao L, I Brunner H, Bonf&#xe1; E, Emi Aikawa N, Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022;31:97&#x2013;104. doi: 10.1177/09612033211062515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211062515</ArticleId><ArticleId IdType="pubmed">34965782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus. 2020;29:52&#x2013;57. doi: 10.1177/0961203319890007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319890007</ArticleId><ArticleId IdType="pubmed">31793379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, McGwin G, Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vil&#xe1; LM. Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61:830&#x2013;839. doi: 10.1002/art.24538.PMID:19479701;PMCID:PMC2898742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24538.PMID:19479701;PMCID:PMC2898742</ArticleId><ArticleId IdType="pmc">PMC2898742</ArticleId><ArticleId IdType="pubmed">19479701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, Aguirre C. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577&#x2013;583. doi: 10.1177/0961203306071872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306071872</ArticleId><ArticleId IdType="pubmed">17080912</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Al&#xe9;n J, Bastian HM, Vil&#xe1; LM, Reveille JD (2007) LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168&#x2013;1172.&#xa0;10.1136/ard.2006.068676. Epub 2007 Mar 27 PMID: 17389655; PMCID: PMC1955128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955128</ArticleId><ArticleId IdType="pubmed">17389655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JW, Kim YY, Lee H, Park SH, Kim SK, Choe JY. Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine. J Rheumatol. 2017;44:1674&#x2013;1679. doi: 10.3899/jrheum.170158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170158</ArticleId><ArticleId IdType="pubmed">28864645</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453&#x2013;1460. doi: 10.1001/jamaophthalmol.2014.3459.Erratum.In:JAMAOphthalmol.2014Dec;132(12):1493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459.Erratum.In:JAMAOphthalmol.2014Dec;132(12):1493</ArticleId><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>